Apollon Wealth Management LLC Buys 3,661 Shares of Edwards Lifesciences Co. (NYSE:EW)

Apollon Wealth Management LLC raised its holdings in Edwards Lifesciences Co. (NYSE:EW) by 21.0% in the fourth quarter, Holdings Channel reports. The fund owned 21,057 shares of the medical research company’s stock after acquiring an additional 3,661 shares during the period. Apollon Wealth Management LLC’s holdings in Edwards Lifesciences were worth $1,606,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of EW. Nordea Investment Management AB raised its position in Edwards Lifesciences by 1,224.1% during the 4th quarter. Nordea Investment Management AB now owns 1,610,412 shares of the medical research company’s stock worth $123,261,000 after purchasing an additional 1,488,791 shares during the last quarter. Telos Capital Management Inc. lifted its stake in shares of Edwards Lifesciences by 158.2% in the 4th quarter. Telos Capital Management Inc. now owns 91,405 shares of the medical research company’s stock valued at $6,970,000 after purchasing an additional 56,000 shares during the period. Arlington Trust Co LLC lifted its stake in shares of Edwards Lifesciences by 5,092.4% in the 4th quarter. Arlington Trust Co LLC now owns 12,306 shares of the medical research company’s stock valued at $938,000 after purchasing an additional 12,069 shares during the period. Versor Investments LP lifted its stake in shares of Edwards Lifesciences by 83.3% in the 3rd quarter. Versor Investments LP now owns 4,496 shares of the medical research company’s stock valued at $311,000 after purchasing an additional 2,043 shares during the period. Finally, HealthInvest Partners AB acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at about $1,587,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Performance

Shares of EW stock traded down $0.53 during trading on Wednesday, hitting $85.31. The company’s stock had a trading volume of 427,157 shares, compared to its average volume of 3,698,005. The company has a market cap of $51.41 billion, a PE ratio of 37.00, a P/E/G ratio of 3.59 and a beta of 1.10. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08. The business has a fifty day moving average of $90.05 and a 200-day moving average of $79.69. Edwards Lifesciences Co. has a 52 week low of $60.57 and a 52 week high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The company had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.58 billion. As a group, research analysts anticipate that Edwards Lifesciences Co. will post 2.77 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 11,000 shares of the stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $85.83, for a total transaction of $944,130.00. Following the sale, the vice president now owns 39,503 shares in the company, valued at $3,390,542.49. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, VP Jean-Luc M. Lemercier sold 14,400 shares of the stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $84.21, for a total value of $1,212,624.00. Following the sale, the vice president now owns 173,849 shares in the company, valued at $14,639,824.29. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 11,000 shares of the stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $85.83, for a total value of $944,130.00. Following the completion of the sale, the vice president now owns 39,503 shares in the company, valued at approximately $3,390,542.49. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 237,749 shares of company stock worth $20,920,934. Insiders own 1.27% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on EW. Wells Fargo & Company boosted their price objective on Edwards Lifesciences from $94.00 to $99.00 and gave the company an “overweight” rating in a research note on Friday, April 26th. Oppenheimer upped their price target on Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a research note on Monday, March 18th. OTR Global raised Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research note on Tuesday, March 26th. Royal Bank of Canada upped their price target on Edwards Lifesciences from $95.00 to $101.00 and gave the stock an “outperform” rating in a research note on Monday, April 15th. Finally, StockNews.com raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Monday, April 29th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $93.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.